Redeye updates estimates and valuation on Stillfront following the company’s Q3-results which came i...
While Q3 was still burdened by high costs, we note the market environment looks to be starting to im...
Atria's Q3 adjusted EBIT of EUR 16.2m was in line with our expectations, supported by strong sales g...
Redeye retains its positive view of Fortnox despite somewhat lowering its short-term forecasts and r...
Redeye believes Formpipe’s Q3 was on the softer side due to the lower-than-expected ACV, following p...
Fortsatt stark efterfrågan… Lagercrantz växte försäljningen 11% organiskt och är därmed på rekordhög...
Redeye leaves its view on Pila Pharma following its report for the third quarter of 2022.
Tillväxten avtar i Q3 Bubblerooms omsättning för Q3 växte 2% i jämförbara enheter till 91,5 mkr.
Q3 svagare y/y på grund av satsningar på Online Bokusgruppen rapporterade en EBITA på 14,9 mkr, lägr...
Redeye is positive as regards the results from a new study, further showing statistically significan...
Q3: EBITDA NOK 21m vs our NOK 24m E-com investment levels to come down from here Estimates likely lo...
Volume decline and continued high input costs in Q3 EBIT lowered 3% for ’22e-’23e, ’24e mostly uncha...
+3% return in Q3… …driven by +6% in NAV and +2pp in discount NAV discount now 27% vs.
Q3 report softer than anticipated We decrease our ’23e-‘24e EBITA ests.
Detection Technology’s Q3 topline came in strong. Net sales growth continued but profitability was h...
The end demand has remained good for Scanfil’s services.
Katalysen meddelade att bolaget har genomfört en riktad nyemission om 7,6 MSEK till strategiska inve...
Dovre’s Q3 results were clearly above our estimates as all three segments recorded figures higher th...
Redeye considers BIMobject’s figures to be overall in line with estimates.
Redeyes view on the Q3 report. The report was weak, in our opinion, even considering the challenges ...
